• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Progression of stroke risk in patients aged & lt;65 years diagnosed with atrial fibrillation: a cohort study in general practice
CONCLUSION: People aged <65 years with AF are at higher risk of developing hypertension, heart failure, and diabetes than the general population, so may warrant regular review to identify new occurrence of such risk factors.PMID:37487643 | DOI:10.3399/BJGP.2022.0568
Source: The British Journal of General Practice - July 24, 2023 Category: Primary Care Authors: Silvia C Mendon ça Duncan A Edwards Jenny Lund Catherine L Saunders Jonathan Mant Source Type: research

Supermarket trolley sensors could help to identify risk of stroke, say scientists
Study with 2,155 participants at Sainsbury ’s stores leads to atrial fibrillation diagnosis for 39 people unaware they had conditionSupermarket trolleys may be known for their wonky wheels and rusty frames, but researchers say the carts could be used to save lives by helping to identify people at risk of stroke through sensors in their handles.According to the British Heart Foundation, one in 45 people in the UK are living with atrial fibrillation (AF), which causes an abnormal heart rhythm and can increase the risk of stroke. While people may be unaware they have the condition, early detection and diagnosis is important...
Source: Guardian Unlimited Science - June 23, 2023 Category: Science Authors: Nicola Davis Science corespondent Tags: Stroke Supermarkets Health Heart disease Medical research Science Society Source Type: news

Barriers and enablers to healthcare system uptake of direct oral anticoagulants for stroke prevention in atrial fibrillation: a qualitative interview study with healthcare professionals and policy makers in England
Conclusions The findings contribute to the wider literature by providing a new and in-depth understanding on the uptake of DOACs. The findings may be applicable to other new medicines used in chronic health conditions.
Source: BMJ Open - April 25, 2023 Category: General Medicine Authors: Medlinskiene, K., Richardson, S., Petty, D., Stirling, K., Fylan, B. Tags: Open access, Qualitative research Source Type: research

Cost-effectiveness of targeted screening for non-valvular atrial fibrillation in the United Kingdom in older patients using digital approaches
CONCLUSIONS: Screening for NVAF at ≥75 years of age could result in fewer NVAF-related strokes. NVAF screening is cost-effective and may be cost-saving depending on the program chosen.PMID:36757910 | DOI:10.1080/13696998.2023.2179210
Source: Journal of Medical Economics - February 9, 2023 Category: Health Management Authors: Shreeya Patel Thitima Kongnakorn Andreas Nikolaou Yassir Javaid Ruth Mokgokong Source Type: research

Atrial fibrillation in UK South Asian hospitalized ischemic stroke patients: The BRAINS study
by Taylor Aurelius, Gie Ken-Dror, Sapna D. Sharma, Sageet Amlani, Gunaratnam Gunathilagan, David L. Cohen, Chakravarthi Rajkumar, Stuart Maguire, Sissi Ispoglou, Ibrahim Balogun, Anthea Parry, Lakshmanan Sekaran, Hafiz Syed, Enas Lawrence, Ravneeta Singh, Ahamad Hassan, Chris Wharton, Khalid Javaid, Neetish Goorah, Peter Carr, Eman Abdus Sami, Pankaj Sharma IntroductionSouth Asian diaspora comprise one of the largest ethnic minority groups in the world yet data about atrial fibrillation (AF) in this demographic is understudied. Our aim is to identify differences in AF prevalence and treatment between South Asians and white...
Source: PLoS One - February 7, 2023 Category: Biomedical Science Authors: Taylor Aurelius Source Type: research

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
CONCLUSION: Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.PRIMARY FUNDING SOURCE: None.PMID:36315950 | DOI:10.7326/M22-0511
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Wallis C Y Lau Carmen Olga Torre Kenneth K C Man Henry Morgan Stewart Sarah Seager Mui Van Zandt Christian Reich Jing Li Jack Brewster Gregory Y H Lip Aroon D Hingorani Li Wei Ian C K Wong Source Type: research

Pages: 1  2  3  4  5  6  7